The emergence of dual-action receptor agonists in the approach of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://apriltyup321525.articlesblogger.com/61206211/retatrutide-vs-tirzepatide-a-comparative-analysis